CDK4/6-targeted therapy for gastrointestinal cancers: from resistance mechanisms to immuno-combination strategies guided by biomarkers - Takeaways - MDSpire

CDK4/6-targeted therapy for gastrointestinal cancers: from resistance mechanisms to immuno-combination strategies guided by biomarkers

  • By

  • Junhao Cui

  • Yanchuan Zhang

  • Yongfang Wu

  • Guangjie Zhang

  • Jie Lan

  • Yingshuang Wang

  • June 4, 2026

  • 0 min

Share

  • 1

    Gastrointestinal cancers have high morbidity and mortality, necessitating novel targeted therapies due to limited treatment options.

  • 2

    CDK4/6 inhibitors, effective in breast cancer, show potential in GI cancers by targeting cell cycle regulation and remodeling the tumor immune microenvironment.

  • 3

    Resistance to CDK4/6 inhibitors in GI cancers arises from dysregulation of the CDK4/6-RB pathway and complex tumor microenvironments.

  • 4

    Biomarker detection and precision molecular subtyping are crucial for identifying patients who may benefit from CDK4/6 inhibitor therapies.

  • 5

    Combination strategies with CDK4/6 inhibitors, including immune checkpoint inhibitors, are essential to enhance efficacy and overcome resistance.

Original Source(s)

CDK4/6-targeted therapy for gastrointestinal cancers: from resistance mechanisms to immuno-combination strategies guided by biomarkers

  • by Junhao Cui, Yanchuan Zhang, Yongfang Wu, Guangjie Zhang, Jie Lan, Yingshuang Wang

  • June 4, 2026

Related Content

Prognostic significance and model evaluation of the modified advanced lung cancer inflammation index in locally advanced resectable gastric cancer patients with neoadjuvant chemotherapy

Automated bone marrow cell classification using ensemble learning: performance, generalization, and clinical interpretability

Towards ultra-fast treatments: large energy acceptance beam delivery systems and opportunities for proton beam therapy